"This award will allow Acorda to obtain more competitive market rates for the supply of AMPYRA, significantly reducing our cost of goods and meaningfully increasing the product's value to the company," said Ron Cohen, M.D., Acorda's President and CEO. "This will also help Acorda to continue to provide its customary high level of support for Ampyra, ensuring that as many people with MS as possible may benefit from it."
News 
Market Data 
Discover 
